Deadline: 17-Mar-2026
The Pfizer MIBC Care Optimization Grant supports projects across Canada that aim to improve care delivery, treatment integration, and patient outcomes for individuals with muscle-invasive bladder cancer (MIBC). With CAD 300,000 in total funding and grants ranging from CAD 50,000 to CAD 300,000, the initiative prioritizes practical, collaborative solutions that address gaps in the MIBC care pathway.
The Pfizer Foundation has launched a competitive grant opportunity to support initiatives that strengthen and modernize the care of patients with muscle-invasive bladder cancer (MIBC) across Canada.
This funding opportunity is designed to improve treatment strategies, enhance patient outcomes, and address systemic gaps in the current MIBC care continuum. The focus is on projects that can deliver tangible, short-term impact while contributing to longer-term improvements in standards of care and patient quality of life.
Purpose and Objectives of the Grant
The primary objective of this grant is to improve how patients with MIBC move through diagnosis, treatment, and post-treatment care.
Funded projects should aim to:
Improve integration of perioperative treatments
Address critical gaps in the MIBC patient journey
Enhance coordination between specialists and care settings
Support scalable solutions that benefit community clinical practice
Improve patient experience and clinical outcomes
Key Focus Areas and Priority Topics
Proposals should address one or more of the following priority areas related to MIBC care optimization:
Reducing waiting times across the MIBC diagnosis and treatment pathway
Establishing clear, efficient referral pathways for newly diagnosed MIBC patients
Implementing flexible multidisciplinary care models, especially in low-resource settings
Designing care models that function within a single institution or across multi-institution collaborations
Optimizing patients’ health and lifestyle prior to cystectomy (prehabilitation initiatives)
Establishing non–MD-led adverse events management clinics, led by trained healthcare professionals from other disciplines, with physician involvement as appropriate
The Pfizer Foundation encourages applicants to focus on practical implementation rather than purely theoretical or exploratory work.
Who Is Eligible to Apply?
Eligible applicants include organizations committed to healthcare improvement in Canada, such as:
Healthcare institutions and hospital systems
Professional medical or healthcare organizations
Government agencies
Other entities dedicated to improving healthcare delivery
The applicant must:
Be based in Canada or conducting the project in Canada
Serve as the Project Lead or Principal Investigator within the requesting organization
Demonstrate the capacity to deliver and manage the proposed project
Multi-institution and inter-professional collaborations are strongly encouraged.
Funding Amount and Project Duration
The total funding available under this opportunity is CAD 300,000.
Individual project requests may range from:
Minimum: CAD 50,000
Maximum: CAD 300,000
Project timelines:
Projects are ideally completed within 12 months
The maximum allowable duration is 24 months
Budgets should be realistic, well-justified, and aligned with project objectives.
Why This Grant Matters
Muscle-invasive bladder cancer is a complex condition that requires timely diagnosis, coordinated care, and multidisciplinary treatment planning. Delays, fragmented pathways, and resource limitations can negatively affect outcomes and patient quality of life.
This grant supports:
Improved care coordination and efficiency
Reduced delays in diagnosis and treatment
Better integration of multidisciplinary expertise
Stronger patient-centered models of care
System-level improvements that can be replicated across Canada
How the Grant Works
Applicants are expected to propose solutions that can be realistically implemented within clinical settings and demonstrate measurable improvement in MIBC care delivery.
Projects should clearly define:
The specific care gap being addressed
The proposed intervention or model of care
Expected short-term and longer-term outcomes
How success will be measured
Plans for collaboration, scalability, or broader adoption
Common Mistakes to Avoid
Proposals that do not focus specifically on muscle-invasive bladder cancer
Projects lacking a clear implementation or evaluation plan
Overly broad initiatives without defined, measurable outcomes
Budgets that are not aligned with proposed activities
Applications without a clearly identified Project Lead or Principal Investigator
Frequently Asked Questions (FAQ)
1. Is this grant limited to academic research projects?
No. The grant supports care optimization initiatives, including service delivery, pathway redesign, and multidisciplinary care models, not only traditional research.
2. Can multiple institutions apply together?
Yes. Multi-institution collaborations are encouraged and viewed favorably.
3. What is the maximum funding amount per project?
Projects may request up to CAD 300,000.
4. How long can a project run?
Projects should ideally be completed within 12 months, with a maximum duration of 24 months.
5. Are non-physician-led initiatives eligible?
Yes. Projects such as non–MD-led adverse events management clinics are specifically encouraged, provided appropriate physician involvement is included.
6. Who can serve as the Project Lead?
The Project Lead or Principal Investigator must be affiliated with the applying organization and responsible for project delivery.
7. Does the project need to benefit patients nationwide?
Projects may be local or regional but should demonstrate potential for broader impact or replication.
Conclusion
The Pfizer Foundation MIBC Care Optimization Grant provides a significant opportunity to improve how muscle-invasive bladder cancer is managed across Canada. By supporting practical, collaborative, and patient-centered initiatives, the program aims to close care gaps, enhance outcomes, and strengthen the overall MIBC care continuum for patients nationwide.
For more information, visit Pfizer.